NCT06039449Phase 3Completed

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-11-19Actual

Enrollment · participants790Actual

Source updated2024-12-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

COVID-19; SARS-CoV-2

Treatments or interventions studied

VYD222 (pemivibart)Drug
Normal salineDrug

Primary outcomes · main study measures

measure: Cohort A - Incidence of treatment emergent adverse events; timeFrame: Through Month 12; measure: Cohort A - Ratio of SARS-CoV-2 sVNA titer against a relevant variant following VYD222 administration at Day 28 compared to a prespecified SARS-CoV-2 sVNA titer threshold.; timeFrame: Day 28; measure: Cohort B - Incidence of treatment emergent adverse events; timeFrame: Through Month 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history